Evidence map›Paper›PMID 22567287›Full record

ArticleMultiple sclerosis international2012

Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial.

Vahid Shaygannejad, Mohsen Janghorbani, Fereshteh Ashtari, Hamed Dehghan

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01753375 (Role of Vitamin D on the Relapse Rate of Multiple Sclerosis), which is not on this map. Cited by 42 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01753375 phase2unknown statusnot on this mapstarted 2013, after this paper: background citation

Role of Vitamin D on the Relapse Rate of Multiple Sclerosis

TypeinterventionalSponsorAlJohara M AlQuaiz, M.D.Ran2013 to 2014Enrolled200ConditionsMultiple SclerosisArmsVitamin D3, Placebo
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Role of lipoic acid in multiple sclerosis.CNS neuroscience & therapeutics · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Vitamin D for the management of multiple sclerosis.The Cochrane database of systematic reviews · 2018
    Pooled it
  8. Pooled it
  9. Review
  10. Review
  11. Observational
  12. Vitamin D in Neurological Diseases.International journal of molecular sciences · 2022
    Review
  13. The Association Between Vitamin D Level and PFAPA Syndrome: A Systematic Review.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vahid ShaygannejadDepartment of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 8144503500, Iran.
Mohsen Janghorbani
Fereshteh Ashtari
Hamed Dehghan

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this preliminary study was to evaluate the effect of low-dose oral vitamin D in combination with current disease-modifying therapy on the prevention of progression of relapsing-remitting multiple sclerosis (RRMS). A phase II double-blind placebo-controlled randomized clinical trial conducted between October 2007 and October 2008 included 50 patients with confirmed RRMS aged 25 to 57 years and normal serum 25-hydroxyvitamin D. They were randomly allocated to receive 12 months of treatment with either escalating calcitriol doses up to 0.5 μg/day or placebo combined with disease-modifying therapy. Response to treatment was assessed at eight-week intervals. In both groups, the mean relapse rate decreased significantly (P < 0.001). In the 25 patients treated with placebo, the mean (SD) Expanded Disability Status Scale (EDSS) increased from 1.70 (1.21) at baseline to 1.94 (1.41) at the end of study period (P < 0.01). Average EDSS and relapse rate at the end of trial did not differ between groups. Adding low-dose vitamin D to routine disease-modifying therapy had no significant effect on the EDSS score or relapse rate. A larger phase III multicenter study of vitamin D in RRMS is warranted to more assess the efficacy of this intervention.

Identifiers

PMID22567287
PMCPMC3337486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.